Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Carlos Jiménez-CorteganaNatalia Palazón-CarriónAlejandro Martin Garcia-SanchoEsteban Nogales-FernandezFernando Carnicero-GonzálezEduardo Ríos-HerranzFatima de la Cruz-VicenteGuillermo Rodríguez-GarcíaRubén Fernández-ÁlvarezAntonio Rueda DominguezMaria Casanova-EspinosaNatividad Martínez-BanaclochaJosep Gumà-PadròJosé Gómez-CodinaJorge LabradorAntonio Salar-SilvestreDelvys Rodriguez-AbreuLaura Galvez-CarvajalMariano ProvencioMargarita Sánchez-BeatoMaría Guirado-RisueñoPablo Espejo-GarcíaMarylene LejeuneTomás ÁlvaroVíctor Sánchez-MargaletLuis de la Cruz Merinonull nullnull nullnull nullPublished in: Journal for immunotherapy of cancer (2021)
In conclusion, blood concentration of MDSCs and Treg cells may be good prognostic markers for overall survival after 2 years in R/R DLBCL. These results point to a possible role of these elements in the immunosuppression of these patients, as assessed by the circulating activated and inhibited T lymphocytes, and therefore, they may be considered as therapeutic targets in DLBCL.
Keyphrases
- diffuse large b cell lymphoma
- regulatory t cells
- induced apoptosis
- epstein barr virus
- cell cycle arrest
- end stage renal disease
- dendritic cells
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- endoplasmic reticulum stress
- cell death
- study protocol
- peritoneal dialysis
- oxidative stress
- phase iii
- cell proliferation
- immune response
- pi k akt
- patient reported outcomes